Skip to main content
. 2020 Dec 22;23(2):164. doi: 10.3892/mmr.2020.11803

Figure 1.

Figure 1.

S100A16 is decreased in human colorectal cancer. (A)Analysis of S100A16 expression in normal colorectal tissues and colorectal adenocarcinoma tissues in the Skrzypczak in Oncomine microarray dataset, as assessed using an unpaired-t test. P<0.05. (B) Representative images of S100A16 protein expression in CRC tumour tissues and paired normal adjacent tissues, as assessed via immunohistochemistry. Magnification, ×400. **P<0.01, paired Students t-test. (C) Representative images of difference scores indicating S100A16 protein expression in CRC tumour tissues and paired normal adjacent tissues (magnification, ×400). The proportion of S100A16-expressing in CRC tissue samples was also analysed. **P<0.01, χ2 test. S100A16 (D) mRNA and (E) protein expression in CRC cell lines, as determined via reverse transcription-quantitative PCR and western blotting, respectively. (F) Kaplan-Meier analysis of the survival rates in patients with CRC with S100A16 low or high expression. CRC, colorectal cancer; S100A16, S100 calcium binding protein A16, IRS, immunoreactive score.